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Abstract
Background: Enoyl-ACP reductase (ENR) catalyses the last reduction reaction in the fatty acid elongation cycle in bacteria
and is a good antimicrobial target candidate. FabV is the most recently discovered class of ENR, but we lack information
about the atomic structure and the key residues involved in reductase activity except for the known conserved tyrosine and
lysine residues in the Y-X8-K active site motif.
Methodology/Principal Findings: Here we report the crystal structure of FabV from Xanthomonas oryzae (xoFabV). The
crystal structure of this enzyme has been solved to 1.6 A ˚ resolution in space group P212121. The model of xoFabV consists of
one monomer in the asymmetric unit which is composed of 13 a-helices and 11 b-strands, representing a canonical
Rossmann fold architecture. Structural comparison presents that the locations of the conserved tyrosine (Y236) and lysine
(K245) residues in the Y-X8-K active site motif of xoFabV and the Y-X6-K motif of ecFabI are notably similar. However, the
conformations of Y236 in xoFabV and Y156 in ecFabI are distinct. Structure-based site-directed mutagenesis and enzymatic
activity assays reveal that in addition to the conserved Y236 and K245 in the Y-X8-K motif, Y53, D111 and Y226 are key
residues implicated in the reductase activity, and F113 and T276 are also important for enzyme function. Moreover, a
proposed active lysine located immediately after the Y-X8-K motif in FabV from Burkholderia mallei (bmFabV) is altered to an
inactive V246 in xoFabV.
Conclusions/Significance: We determine the first crystal structure of the FabV enzyme and identify several residues
important for its enzymatic activity. These findings lay a solid foundation for the development of specific antibacterial
inhibitors of the pathogenic bacteria, such as Vibrio cholerae, Burkholderia species and Xanthomonas species.
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Introduction
Fatty acid synthesis (FAS) is critical for many organisms except
the archaea. The cytosol of mammalian cells and fungi utilise the
FAS I system in which the active sites reside in one and two
multifunctional proteins, respectively. The FAS II system in
bacteria (and in plants, apicomplexan protozoa and mitochondria)
uses several discrete monofunctional enzymes that catalyse each
single reaction, which makes these enzymes attractive targets for
specific antibacterial agents [1,2]. In particular, enoyl-ACP
reductase, which catalyses the last reduction reaction in the fatty
acid elongation cycle using trans-2-acyl-ACP as the substrate in an
NAD(P)H-dependent manner, is a vital enzyme and, therefore, is a
promising antimicrobial target. At present, four distinct ENR
members, FabI, FabL, FabK and FabV, have been identified.
FabI is a member of the short-chain dehydrogenase/reductase
(SDR) superfamily, and its coenzyme-binding site has the classical
Rossmann fold motif. The homologues from Escherichia coli
(ecFabI) and Mycobacterium tuberculosis (InhA) both have the Y-X6-
K motif in which the conserved tyrosine protonates the substrate
enoyl-thioester and the lysine interacts with the hydroxyl groups of
the nicotinamide ribose moiety [1]. FabIs from various bacteria
can be inhibited effectively by triclosan, isoniazid or diazaborine
through the formation of a FabI-NAD(H)-inhibitor ternary
complex [3–7]. The interaction between FabI and NAD
+ is weak
[3]; however, FabI can bind strongly to NAD
+ in the presence of
diazaborine or triclosan [3,6]. Like FabI, FabL from Bacillus subtilis
(bsFabL) is a member of the SDR superfamily and possesses a
Rossmann fold structure and the Y-X6-K motif [8]. It is reversibly
inhibited by triclosan but does not form a stable ternary complex
with NAD
+ and triclosan [9]. Interestingly, FabK is unrelated to
the SDR family. It is a triclosan-resistant flavoprotein [10] that
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rather than the Rossmann fold structure.
FabV is the most newly discovered class of ENR [2]. It exists in
a variety of organisms, including some clinically important
pathogens and serious plant pathogens, such as Vibrio cholerae,
Yersinia pestis, Pseudomonas aeruginosa, Burkholderia species and
Xanthomonas species. FabV from V. cholerae (vcFabV) consists of
402 residues and exists as a monomer protein in solution. It is
active with both crotonyl-ACP and the model substrate crotonyl-
CoA; in addition, FabV strongly prefers NADH to NADPH, and
it could not be inhibited effectively by triclosan, even in the
presence of NAD
+. Through the kinetic and mutagenesis studies of
FabV from Burkholderia mallei (bmFabV) [12], two conserved active
site residues, tyrosine (Y235) and lysine (K244), were found to be
organised in a Y-X8-K motif. Furthermore, a second conserved
lysine (K245) residue was identified. Although another conserved
tyrosine (Y225) was indicated, no further information was given.
Finally, a hydrogen bonding network among these three active
residues (Y235, K244 and K245), the cofactor and the enoyl-ACP
substrate was proposed. In the hypothetical model, Y235 stabilises
the enoyl-ACP substrate and interacts with K244 via a hydrogen
bond between the hydroxyl group of Y235 and the side chain
nitrogen atom of K244; K244 interacts with both the cofactor
NADH and the substrate, while K245 only interacts with the
substrate.
Up to now, no crystal structure of any FabV enzyme has been
determined. Here, we report the whole structure of xoFabV from
X. oryzae, a serious pathogen that causes blight disease in rice [13],
and we identify the key active residues involved in the reductase
activity.
Results and Discussion
Crystal structure of xoFabV
The native xoFabV consists of 402 residues, excluding the N-
terminal His tag and thrombin cleavage site, with a molecular
mass of 45,800 Da. We successfully crystallised the full-length
selenomethionine-substituted xoFabV (SeMet-xoFabV) without
removing the N-terminal His tag and the thrombin cleavage site.
The crystals diffracted to 1.6 A ˚ resolution under synchrotron
illumination (Table 1). Phase information was obtained by two-
wavelength MAD phasing.
The SeMet-xoFabV crystal contains one monomer in the
asymmetric unit. The density map was of high quality and allowed
us to build an almost complete model containing 390 residues
(C12-L401) but lacking the His tag and thrombin cleavage site at
the N-terminus and A402. Each xoFabV monomer consists of 13
a-helices (a1–a13) and 11 b-strands (b1–b11) (Fig. 1). Strands
b1–b4 and b9 – 11 form a parallel b-sheet located at the centre of
the structure. This b-sheet is flanked on one side by helices a2, a3
and a10 and on the other by helices a4–a7, which, taken
together, constitute the canonical Rossmann fold centre. The
other helices and strands are located around the fold centre.
Unlike the strands constituting the b-sheet, strands b5–b6 and b7
– b8 form two anti-parallel hairpin structures.
Structural comparison of xoFabV and ecFabI
To find the potential catalytic residues implicated in the
reductase activity of xoFabV and to compare the structural
differences between xoFabV and its homologue, the structures of
xoFabV and chain A of ecFabI (PDB id: 1MFP, ecFabI complexed
with NAD
+ and the inhibitor SB611113 [14]) were superposed
using the SSM Superpose function [15] of COOT [16]. Because
ecFabI is the most researched homologue of the ENR superfamily
and many ternary structures of ecFabI have been resolved
[7,17,18], 1MFP was chosen as a representative for the structural
comparison. Although both xoFabV and ecFabI have Rossmann
fold architectures, their overall structures differ dramatically
(Fig. 2). The b-sheet and its flanking a-helices constituting the
fold centre are shifted, and xoFabV is considerably larger (402
residues) than ecFabI (262 residues) and has additional secondary
structures, including helices a1 and a11 – a13 and strands b5–b8
and b11. However, the functions of these additional secondary
structures in xoFabV are still unknown.
Although there was obvious conformational variation between
the overall structures of xoFabV and ecFabI, potential active site
residues of xoFabV were selected via sequence alignment for
detailed conformational comparison (Table 2). First, we selected
the residues of ecFabI that are involved in interaction with NAD
+
as indicated by LIGPLOT analysis [19]. These residues include
Table 1. X-ray diffraction data collection and refinement
statistics.
Data collection
Se Peak Se Edge
Wavelength (A ˚) 0.97902 0.97930
Resolution range (A ˚)2 0 21.60 (1.6621.60)
a 2021.60 (1.6621.60)
Unique reflections 54,290 (5,366) 54,322 (5,380)
Completeness (%) 99.9 (100.0) 99.9 (100.0)
Redundancy 14.3 (14.6) 14.3 (14.6)
Rmerge (%) 7.0 (20.5) 6.2 (20.9)
,I/s(I). 64.0 (16.4) 63.5 (15.6)
Solvent (%) 44.2% 44.2%
Space group P212121 P212121
Unit cell (A ˚) a=50.52 a=50.52
b=74.52 b=74.52
c=107.39 c=107.39
Refinement statistics
Resolution range (A ˚) 19.8921.60 (1.6621.60)
Residues/ASU
b 390
Water molecules/ASU 277
Rwork (%)
c 18.5 (14.7)
Rfree (%)
d 20.5 (18.7)
RMSD bond length (A ˚) 0.006
RMSD bond angle (
o) 1.009
Average B-factors (A ˚2) 14.4
Protein 14.1
Water molecules 18.0
Ramachandran Plot
In most favoured regions (%) 93.2
In additional allowed regions (%) 6.8
In generously allowed regions (%) 0
In disallowed regions (%) 0
aValues in parentheses are for the highest resolution shell.
bASU, asymmetric unit.
cRwork=S||Fobs|–|Fcalc||/S|Fobs|, where Fcalc and Fobs are the calculated and
observed structure factor amplitudes, respectively.
dRfree=asforRwork, but for 3.7% of the total reflections chosen at random and
omitted from refinement.
doi:10.1371/journal.pone.0026743.t001
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T194 of ecFabI, and the corresponding residues in xoFabV, Y53,
D111, F113, Y226, K245 and T276, respectively. Second, we
selected Y156, the conserved tyrosine in the Y-X6-K motif of
ecFabI that interacts with the inhibitor SB611113 via hydrogen
bonding and the corresponding residue in xoFabV, Y236 (Fig. 3).
Structural comparison showed that the locations of the
conserved tyrosine and lysine residues in the Y-X8-K motif of
xoFabV and the Y-X6-K motif of ecFabI were notably similar,
despite the fact that there are two more residues in the former than
the latter. However, the conformations of Y236 of xoFabV and
Y156 of ecFabI are different (Fig. 4). The side chains of the two
tyrosines point to different directions. In ecFabI, Y156 points to
K163, and the distance between the oxygen atom of the hydroxyl
group in Y156 and the nitrogen atom of the K163 side chain is
about 4.5 A ˚. In xoFabV, Y236 does not point to K245, and the
distance is 10.4 A ˚. The conformations of K163 of ecFabI and
K245 of xoFabV are almost identical; they are in the same
position, and their side chains point in the same direction. This
could be explained by the fact that they are both in a long helix
(K245 of xoFabV in helix a7) and are not flexible enough to
change conformation. The difference between the distances of the
conserved tyrosine and lysine residues might lead to the variations
in their abilities to bind the substrate, cofactor or inhibitor. As for
the other residues being compared, D111, Y226 and T276 of
xoFabV are conserved in ecFabI, and the residues corresponding
to Y53 and F113 of xoFabV have been substituted with different
amino acids in ecFabI.
Figure 1. Crystal structure of xoFabV. The structure consists of 13 a-helices and 11 b-strands, representing a classic Rossmann fold architecture.
The secondary structures are shown in different colours and are labelled with the corresponding numbers. (A) Side view. (B) Top view. Figures 1–4
were made using PyMOL (DeLano Scientific, Palo Alto, California, USA; http://www.pymol.org).
doi:10.1371/journal.pone.0026743.g001
Figure 2. Overall structural comparison of xoFabV and ecFabI. The two structures differ dramatically. The b-sheet and the flanking a-helices
are shifted, and xoFabV has additional secondary structures, including helices a1 and a11 – a13 and strands b5–b8 and b11, which are shown in
yellow. Other parts of xoFabV are shown in green; ecFabI is shown in magenta. (A) Side view. (B) Top view.
doi:10.1371/journal.pone.0026743.g002
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bioinformatic and mutagenesis studies of bmFabV suggested that
in addition to the conserved tyrosine (Y235) and the lysine (K244)
residues of the Y-X8-K motif, an adjacent lysine (K245) in
bmFabV also plays an important role in substrate binding.
However, a sequence alignment of vcFabV (YP_001217283.2),
bmFabV (YP_102617.1) and xoFabV using T-Coffee [20,21]
revealed that K245 present in bmFabV (Fig. 5) is altered to a non-
polar valine (V246) in xoFabV.
In addition, we used CD-Search [22] against the Conserved
Domain Database [23] to probe additional potentially key
residues; the results showed that S50 and Y53 (previously
mentioned in the structural comparison) might be involved in
NADH binding.
Plasmid complementation test and NADH oxidation
assay
To determine the interaction network between xoFabV, the
cofactor and the inhibitor, we attempted to co-crystallise xoFabV
with NAD
+ and NAD
+-triclosan with different molar ratios, pre-
incubation times and reservoir solutions. Unfortunately, we failed
to observe electron densities for NAD
+ or triclosan at the expected
binding sites in any of the crystal structures of the supposed
complexes. This could be explained by the fact that NAD
+ binds
weakly to xoFabV according to isothermal titration calorimetry
assay (data not shown) and that triclosan is a rapid, reversible
inhibitor of the FabV enzyme [12]. We also attempted to co-
crystallise the wild-type xoFabV in complex with NADH but were
not able to obtain the complex structure.
As mentioned above, the structures of the potential key residues
of xoFabV and ecFabI are similar, which indicates that these
residues in xoFabV might play a role in reductase activity in a
similar manner to those in ecFabI. To investigate the roles of these
residues in FabV enzymatic activity, we expressed and purified the
following mutants: S50A, Y53A, Y53F, D111A, F113A, Y226F,
Y236A, Y236F, K245A, K245R, V246A and T276A. Because the
N-terminal His tag does not dramatically affect the activity [12],
the tag was not removed by thrombin cleavage. The gel filtration
Table 2. Residues under comparison.
xoFabV
a S50 Y53 D111 F113 Y226 Y236 K245 V246 T276
ecFabI
b V14 I20 D64 V65 Y146 Y156 K163 A164 T194
aS50 and Y53 are the predicted conserved residues in the potential NAD(P)H-binding site; V246 is the corresponding residue of K245 in bmFabV; Y236 and K245 are the
conserved residues in the Y-X8-K motif.
bI20, D64, V65, Y146, K163 and T194 are involved in the interaction with NAD
+; Y156 interacts with the inhibitor SB611113 via a hydrogen bond. Y156 and K163 are the
conserved residues in the Y-X6-K motif.
doi:10.1371/journal.pone.0026743.t002
Figure 3. Structural comparison of individual residues in xoFabV and ecFabI. The individual residues listed in Table 2 are shown in sticks
and balls. Their positions in the overall structures are labelled with circles and are enlarged. The residues of xoFabV are shown in green and are listed
before the hyphen; the residues of ecFabI are shown in magenta and after the hyphen.
doi:10.1371/journal.pone.0026743.g003
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of the wild-type xoFabV enzyme, indicating that any variations in
enzymatic activity resulting from mutagenesis were not caused by
conformational changes.
The expression of xoFabV mutants D111A, Y236A, Y236F,
K245A and K245R in the E. coli fabI (Ts) strain JP1111 [2] did not
restore in vivo fatty acid synthesis at the non-permissive
temperature of 42uC (Fig. 6). Mutant Y53A partly restored fatty
acid synthesis, while S50A, Y53F, F113A, Y226F, V246A and
T276A restored synthesis to the wild-type level. NADH oxidation
was assayed in vitro with the model substrate crotonyl-CoA. Kinetic
parameters were measured only for wild-type xoFabV. The values
of kcat, Km,NADH and Km,Crotonyl-CoA were 13356145 min
21,
18.762.0 mM and 293616.5 mM, respectively (Table 3), indicat-
ing that xoFabV has a similar catalytic efficiency for crotonyl-CoA
compared to bmFabV [12]. For the xoFabV mutants, only
progress curves were measured (Fig. 7). The curves showed that
the enzymatic activities of mutants Y53A, D111A, Y236A, Y236F,
K245A, K245R and T276A were not detected in the NADH
oxidation assay; Y53F and Y226F catalysed the reduction at about
50% efficiency; F113A had a speed that was one sixth that of the
wild-type and mutants S50A and V246A were as efficient as the
wild-type enzyme.
The results of the in vivo plasmid complementation test and the
in vitro oxidation assay illustrate that D111, Y236 and K245 are the
most important residues for reductase activity. All of the mutations
introduced into these three residues completely abolished enzyme
function. D111 of xoFabV corresponds to D64 in ecFabI, which
interacts with NAD
+ via hydrogen bonding through the oxygen
atom of the side chain, and their conformations are similar. Thus,
D111 might also interact with the cofactor in the same manner as
D64 in ecFabI. Y236 and K245 are the conserved tyrosine and
Figure 4. Structural comparison of the Y-X8-K motif of xoFabV
and the Y-X6-K motif of ecFabI. Despite the fact that the Y-X8-K
motif of xoFabV has two more residues than the Y-X6-K motif of ecFabI,
the conformations of the conserved tyrosine and lysine residues are
similar. The distance between the conserved tyrosine (Y236) and lysine
(K245) residues in the Y-X8-K motif of xoFabV (shown in green) is 10.4 A ˚,
while the distance between Y156 and K163 in the Y-X6-K motif of ecFabI
(magenta) is 4.5 A ˚.
doi:10.1371/journal.pone.0026743.g004
Figure 5. Full-length sequence alignment of three enoyl-ACP reductase enzymes from different organisms. The sequences are from V.
cholerae, B. mallei and X. oryzae. Y226, Y236 and K245 of xoFabV and their corresponding residues in the other two enzymes are labelled with
asterisks. V246 of xoFabV and its corresponding residues are labelled with a colon. The sequence alignment was performed using T-Coffee, and the
figure was made using ESPript [34].
doi:10.1371/journal.pone.0026743.g005
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Y156F in ecFabI causes a modest decrease in enzymatic activity
[24], the fact that Y236A and Y236F completely lost their activity
suggests that Y236 plays an essential role in the reduction of the
substrate and that it functions via its hydroxyl group. This residue
might function as its corresponding partner in ecFabI (Y156),
which protonates the enoyl-ACP substrate or binds to the inhibitor
through a hydrogen bond. Mutagenesis of K245A and K245R
both diminish enzymatic activity, indicating that K245 is essential
for the interaction with the cofactor NADH, similarly to the role of
Y163 in ecFabI, and the side chain length of K245 is critical for
binding the cofactor.
Y53, F113 and T276 are also key residues for enzyme function
and might interact with NAD
+ via hydrogen bonds as their
corresponding partners in ecFabI (I20, V65 and T194, respec-
tively). The decreased enzyme activities of mutants Y53A and
Y53F indicate that Y53 probably functions via its aromatic side
chain rather than only by the hydroxyl group. Mutants F113A and
T276A restored fatty acid synthesis in vivo but had much lower
catalytic efficiencies in vitro than the wild-type xoFabV, suggesting
that they played important roles in reductase activity. Residue
Y226 is the second conserved tyrosine located upstream of the Y-
X8-K motif, and its corresponding residue in ecFabI (Y146)
interacts with both the cofactor and inhibitor via hydrophobic
contacts. The variation in the in vitro enzyme activity assay for the
mutant Y226F reveals that this residue is essential.
Residue V246 corresponds to K245 in bmFabV, which is taken
as a second conserved lysine located right after the Y-X8-K motif.
Although K245 in bmFabV has been demonstrated to be involved
in the binding of enoyl substrates and probably functions through
its side chain [12], V246 in xoFabV is not a key residue in this
reaction, which may be due to their different substrate specificities.
Residue S50 was predicted to be involved in the NAD(P)H-
binding site in the CD-Search analysis against the Conserved
Domain Database, but the replacement of this residue with
alanine did not abolish its enzymatic activity, indicating that S50
might not participate in the substrate reduction.
As mentioned above, xoFabV has several additional a-helices
(a1 and a11 – a13) and b-strands (b5–b8 and b11) compared
with ecFabI. However, the functions of these secondary structures
are not known. To explore their possible roles in the reductase
reaction, a CD-Search analysis against the Conserved Domain
Database was performed. The analysis indicated that xoFabV has
a potential FAD-binding site at its C-terminus, which is conserved
as FGFxxxxxDY where x is any residue. In xoFabV, the sequence
is FGFGRTDVDY (residues 377–386). To test the ability of the
wild-type xoFabV enzyme to bind FAD, co-crystallisation and
isothermal titration calorimetry (ITC) assays were performed.
Although the conditions for co-crystallisation between xoFabV
and FAD were optimised, including various molar ratios, pre-
incubation times and reservoir solutions, no convincing electron
density for the FAD molecule could be observed at the predicted
FAD-binding sites in the crystal structures of the supposed
complexes. Also, the ITC assay suggested that the interaction
between xoFabV and FAD might be weak, and no curve could be
fitted according to the titration data. These indicate that the
Figure 6. In vivo plasmid complementation test. The functions of the wild-type and mutant xoFabV genes were validated in the E. coli fabI (Ts)
strain JP1111. Growth conditions at 30uC are before induction with arabinose; growth conditions at 42uC are after induction with arabinose.
doi:10.1371/journal.pone.0026743.g006
Table 3. Kinetic parameters for the wild-type xoFabV
enzyme.
kcat (min
21) Km (mM)
kcat/Km
(mM
21 min
21)
NADH Crotonyl-CoA Crotonyl-CoA
13356145 18.762.0 293616.5 4.560.6
doi:10.1371/journal.pone.0026743.t003
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functions of the additional regions need to be further investigated.
Conclusion
We determined the first crystal structure of the FabV enzyme
with the Y-X8-K motif and discussed the differences between this
motif and the Y-X6-K motif in ecFabI. Also, we identified the key
residues involved in the reductase activity. Based on the in vivo
plasmid complementation test and the in vitro NADH oxidation
assay, D111, Y236 and K245 are found to be the most essential
residues for activity, and Y53, F113, Y226 and T276 are also
important for catalysing substrate reduction. Structure comparison
and the LIGPLOT analysis suggest that i) Y53, D111, F113, K245
and T276 might interact with the NADH cofactor; ii) Y226 might
interact with both the cofactor and substrate (or inhibitor) and iii)
Y236 might interact with the substrate (or inhibitor). These
findings are extremely useful for the development of antibacterial
inhibitors specific for the FabV enzyme in the pathogenic bacteria.
Materials and Methods
Enzyme expression and purification
The Xanthomonas oryzae pv. oryzae KS-1-21 strain [25] was a gift
from Prof. Shiping Wang of Huazhong Agricultural University.
The entire xoFabV gene was amplified by PCR using a single
colony of the KS-1-21 strain as the template. Primers designed for
cloning are listed in Table 4. The gene was inserted into the pET-
28b(+) vector using the 59 Nde I and 39 Hind III restriction sites,
and a sequence encoding a His tag and a thrombin cleavage site
was introduced upstream of the xoFabV gene. The recombinant
SeMet-xoFabV was expressed as described [26] except that the
pET-28b(+) vector and E. coli BL21(DE3) strain were used. After
harvesting the bacteria by centrifugation, the cells were lysed by
sonication in equilibration buffer (50 mM Tris-HCl, 500 mM
NaCl, 50 mM imidazole, pH 8.0), and the lysate was then applied
to Ni
2+-affinity resin (Chelating Sepharose
TM Fast Flow, GE
Healthcare, NJ, USA) in a Poly-Prep
TM chromatography gravity
column (Bio-Rad, CA, USA). After washing the column with
equilibration buffer, the target protein was eluted with Tris-HCl
buffer containing 200 mM imidazole. The protein was purified
using a Superdex
TM 200 (10/300 GL) column in gel filtration
buffer (50 mM Tris-HCl, 100 mM NaCl, 1 mM DTT, pH 8.0).
The xoFabV monomer was collected and concentrated, and its
concentration was measured by the Bradford method.
The xoFabV mutants S50A, Y53A, Y53F, D111A, F113A,
Y226F, Y236A, Y236F, K245A, K245R, V246A and T276A were
constructed using the Easy Mutagenesis Kit (TransGen, Beijing,
China). Primers designed for mutagenesis are listed in Table 4.
The wild-type and mutant xoFabV enzymes were expressed in
BL21(DE3) cells at 16uC, and expression was induced by the
addition of 0.2 mM IPTG for 20 h. The purification procedure
was the same as above, but no DTT was added.
Crystallisation, data collection and structure
determination
SeMet-xoFabV protein crystals were grown using the hanging-
drop vapour diffusion method in a reservoir solution of 100 mM
Bis-Tris (pH 6.5) containing 200 mM NaCl, 1 mM DTT and
15% PEG 3350. Crystals appeared in 24 h and were of high
quality. Two diffraction datasets were collected. The HKL-2000
package [27] was used for data processing. The crystal belonged to
space group P212121, with cell dimensions of a=50.52 A ˚,
b=74.53 A ˚ and c=107.39 A ˚. PHENIX [28] was used for two-
wavelength MAD phasing and automatic model building. One
xoFabV monomer was found in the asymmetric unit, and five out
of the six expected selenium atoms were located in each monomer.
Several iterative rounds of manual building in COOT and
refinement in PHENIX were performed until acceptable Rwork
(18.5%) and Rfree (20.5%) values were achieved. The stereochem-
ical quality of the final model at 1.6 A ˚ was validated using
PROCHECK [29], which showed that 93.2% of the residues are
Figure 7. Progress curve analysis of the wild-type and mutant xoFabV variants in the NADH oxidation assay. The enzyme activity of
wild-type and mutant xoFabV was determined by monitoring the oxidation of NADH to NAD
+ at 340 nm. The reaction was initiated by adding the
substrate crotonyl-CoA and was monitored for 10 min at 25uC.
doi:10.1371/journal.pone.0026743.g007
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6.8% are within the additional allowed region. The Matthews
coefficient [30] was 2.1 A ˚ 3 Da
21, and the solvent content was
44.2%.
Plasmid complementation test and NADH oxidation
assay
To test their abilities to restore in vivo fatty acid synthesis, wild-
type and mutant xoFabV genes were cloned into the arabinose-
inducible pBAD24 vector [31,32] and transformed into the fabI
(Ts) strain JP1111. The cultures were grown at 30uC, induced with
0.02% arabinose and then shifted to 42uC.
The enzyme activities of the wild-type and mutant xoFabVs
were determined by monitoring the oxidation of NADH to NAD
+
at 340 nm using an NADH extinction coefficient of 6220 M
21
[33]. Each 150 mL of reaction mixture contained 75 nM purified
His-tagged xoFabV, 200 mM NADH, 200 mM crotonyl-CoA and
1 mM NaCl in 20 mM Tris-HCl buffer (pH 7.5). The reaction
was initiated by adding the substrate crotonyl-CoA and was
monitored for 10min at 25uC. The kinetic constants of the wild-
type xoFabV enzyme were analysed using Microsoft Excel 2003.
Progress curves of the mutant xoFabV enzymes were constructed
using Origin Pro version 8.0.
ITC assay and co-crystallisation of xoFabV with FAD
The isothermal titration calorimetry assay was performed at
25uC using an iTC200 Microcal calorimeter (Microcal, NJ, USA).
FAD and wild-type xoFabV were both dissolved in ITC buffer
(50 mM Tris-HCl, 100 mM NaCl, pH 8.0). Sixty microliters of
4 mM FAD solution was loaded into the syringe as the ligand, and
250 mL of 200 mM xoFabV was injected into the cell as the
binding partner. The ligand was injected into the protein in 20
drops with 0.5 mL used for the first drop and 2 mL used for the
remaining 19 drops. A stirring speed of 2000 rpm and a time
interval of 120 s between drops were set to ensure that every drop
of ligand solution was completely mixed with the binding partner.
The ligand was titrated into protein-free ITC buffer as a reference,
and the data were analysed using Origin software version 7.0.
Wild-type xoFabV and FAD were mixed at 1:2 to 1:10 molar
ratios and incubated at 4uC for 1 h prior to being co-crystallised
under the same conditions as SeMet-xoFabV but without adding
DTT. The diffraction datasets of the crystals were collected using a
VariMax
TM and MicroMax
TM-007 X-ray generator (Rigaku) at
the Institute of Biophysics, Chinese Academy of Sciences. The
structures were determined with PHENIX by the molecular
replacement method using the SeMet-xoFabV structure as the
search model.
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